CliffBio
small molecule

ARFORMOTEROL TARTRATE

ARFORMOTEROL TARTRATE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameARFORMOTEROL TARTRATE
Active ingredientARFORMOTEROL TARTRATE
StrengthEQ 0.015MG BASE/2ML
Dosage formSOLUTION
RouteINHALATION
ModalitySmall molecule
FDA approvalJune 2021
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ARFORMOTEROL TARTRATE patent cliff — loss of exclusivity — | CliffBio